Royalty Report: Drugs, Cancer, Therapeutic – Collection: 25982

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 25982

License Grant
The Licensee, a subsidiary of the Licensor, entered into a License Agreement with the Licensor, granting an exclusive, worldwide, non-transferable License under its patents and patent applications and in the intellectual property rights related to its know how, to conduct clinical trials, commercialize and distribute NV-128.
License Property
NV-128 is an investigational cancer compound which has been shown in pre-clinical laboratory studies to promote cancer cell death by targeting a pro-survival regulatory pathway (the AKT-mTOR pathway). The NV-128 License Agreement covers the use of NV-128 in the field of prevention, treatment and cure of cancer in humans delivered in all forms except topical applications.

IPSCIO Record ID: 2928

License Grant
An Australian licensor and a U.S. clinical development oncology company (majority owned by licensor) have concluded a Licence Agreement for licensee to develop and commercialize the oncology compound NV-128.
License Property
NV-128 is a cancer compound which has been shown in pre-clinical studies to promote cancer cell death in multi-drug resistant cancer cells by inducing caspase – independent DNA degradation and cancer cell death via the AKT-mTOR pathway.
Field of Use
Licensee will fund the ongoing clinical programs and is responsible for the commercial development of the drug.  Licensee is also the licensee of the licensor developed investigational anti-cancer drugs phenoxodiol and triphendiol that are currently in clinical development.

IPSCIO Record ID: 26695

License Grant
The Australian Company entered into a License Agreement pursuant to which a subsidiary, granted to Licensee a worldwide non-transferable License under its patents and patent applications and in its know-how to conduct clinical trials and commercialize and distribute phenoxodiol products.
License Property
The License is exclusive until the expiration or lapsing of the last relevant the Licensor patents or patent applications in the world and thereafter is non-exclusive.
Field of Use
The License Agreement covers uses of phenoxodiol in the field of prevention, treatment or cure of cancer in humans delivered in all forms except topical applications.

IPSCIO Record ID: 26312

License Grant
The Australian Company entered into a second License Agreement with a subsidiary for two oncology compounds, NV-196 and NV-143. NV-196 is being developed initially in oral form for pancreatic and bile duct cancer and is currently in Phase I human testing.
License Property
NV-143 is targeted for the treatment of melanoma, also in oral dose form, and is in the pre-clinical testing stage.
Field of Use
The License Agreement covers uses of NV-196 and NV-143 in the field of prevention, treatment or cure of cancer in humans delivered in all forms except topical applications.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.